Pleural mesothelioma malignant recurrent – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:00:43 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pleural mesothelioma malignant recurrent – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Pembrolizumab and Lenvatinib for Patients with Malignant Pleural Mesothelioma in Second and Third Line Treatment https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-lenvatinib-for-patients-with-malignant-pleural-mesothelioma-in-second-and-third-line-treatment/ Wed, 29 Apr 2026 14:59:05 +0000 https://clinicaltrials.eu/trial/study-of-pembrolizumab-and-lenvatinib-for-patients-with-malignant-pleural-mesothelioma-in-second-and-third-line-treatment/ This clinical trial is focused on studying a disease called malignant pleural mesothelioma, which is a type of cancer that affects the lining of the lungs. The study is testing a combination of two treatments: pembrolizumab and lenvatinib. Pembrolizumab is a medication that is given through an infusion, which means it is delivered directly into the bloodstream through a vein. Lenvatinib is taken as a capsule by mouth. The purpose of the study is to see how well these two medications work together in treating patients who have already received other treatments for their cancer.

Participants in the study will receive both pembrolizumab and lenvatinib. The study will follow patients over a period of time to observe how their cancer responds to the treatment. Some patients may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment. The study aims to determine the effectiveness of the treatment combination in shrinking or controlling the cancer.

The trial is designed to help understand the potential benefits and side effects of using pembrolizumab and lenvatinib together for treating malignant pleural mesothelioma. By participating in the study, researchers hope to gather valuable information that could lead to better treatment options for this type of cancer in the future.

]]>